Suppression of myocardial injury markers following percutaneous coronary interventions by pre-treatment with carvedilol

ABSTRACT

Retrospective studies and clinical trials have indicated that beta -receptor blockers have an influential role in improving survival and reducing risk of recurrent infarction in patients with myocardial infarction. However, there is still controversy regarding the effects of beta -receptor blockers on the markers of myocardial infarction following percutaneous coronary interventions [PCI]. The aim of this study was to evaluate the pre-treatment effect of Carvedilol on markers of myocardial injury in patients undergoing elective PCI. In this clinical trial patients undergoing elective PCI were categorized randomly in the Carvedilol group including 100 patients who received two doses of 12.5 mg, 6 and 12 hours prior to PCI, and the control group [105 patients]. Blood samples were obtained to analyse cardiac biomarker, 12 and 24 hours after PCI. The clinical features were not significantly different between the two groups. A increase in the level of Troponin I was observed in the control group 24 hours following PCI [P=0.042], whereas this rise in troponin I was slight and insignificant in the Carvedilol group [P>0.05]. some difference was observed between the two groups in regard to the level of CPK-MB after PCI [P=0.041]. The findings of our study indicate that pre-treatment with Carvedilol confers cardio-protection by limiting the rise of markers of myocardial injury following PCI